Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users
- 25 February 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 23 (2) , 148-156
Abstract
There is ongoing development of new therapies for psoriasis, including biologic and systemic agents such as interleukin-17, interleukin-23, and phosphodiesterase-4 inhibitors. The development of these agents has changed the landscape of psoriasis treatment options. The objective of this study was to characterize the impact of newer biologic and systemic agents approved by June 2016 on patient outcomes. We sought to evaluate and compare biologic users and nonbiologic systemic users with respect to their treatment awareness and satisfaction. We conducted a national Canadian survey from July to September 2016 on adult patients with moderate-to-severe psoriasis using biologic agents or nonbiologic systemic agents as their current primary treatment modality. Patients were asked to evaluate their overall satisfaction with their treatment agent and their awareness of other treatment options. Responses from biologic and nonbiologic systemic users were compared. Overall, 343 participants were included (biologic users: n = 218; nonbiologic users: n = 125). Treatment satisfaction: Biologic users had a higher overall satisfaction score than nonbiologic users (P < .001). Among nonbiologic agents, apremilast (62%) was associated with the highest satisfaction proportion. Among biologic agents, ustekinumab (77%) and adalimumab (72%) were associated with the highest proportions of satisfaction. With respect to treatment awareness, 30% of nonbiologic patients did not have enough information to form an opinion about biologics. This study demonstrates the greater treatment satisfaction of biologic users compared with nonbiologic users for moderate-to-severe psoriasis. Given that nearly one-third of nonbiologic users did not have enough information to form an opinion about biologic agents, physicians may consider counselling these patients on the use of biologic agents for psoriasis management.Keywords
Funding Information
- Janssen
This publication has 28 references indexed in Scilit:
- PsoriasisThe Lancet, 2015
- Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective studyJournal of the American Academy of Dermatology, 2015
- Treatment Satisfaction of Patients with PsoriasisActa Dermato-Venereologica, 2015
- Satisfaction with treatment among patients with psoriasis: a web-based survey studyBritish Journal of Dermatology, 2013
- Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapiesJournal of the European Academy of Dermatology and Venereology, 2013
- Living with Psoriasis: Prevalence of Shame, Anger, Worry, and Problems in Daily Activities and Social LifeActa Dermato-Venereologica, 2012
- S3 – Guidelines on the treatment of psoriasis vulgaris (English version). UpdateJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2012
- Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasisJournal of the American Academy of Dermatology, 2006
- European patient perspectives on the impact of psoriasis: the EUROPSO patient membership surveyBritish Journal of Dermatology, 2006
- Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth and Quality of Life Outcomes, 2004